Prostatype Genomics AB

Annual Report 2022

Prostatype Genomics

About Prostatype Genomics

The company is the result of over fifteen years of research work in the genomics of prostate cancer. The company was founded in 2007 as a spin-off from Cancer Center Karolinska (Karolinska Institutet, Stockholm). The result was the development of the today CE-marked and market-ready product Prostatype® Test System. Prostatype® is a test for the prognosis of prostate cancer that has been developed to provide the additional information that is often required to select the optimal treatment strategy for each patient. The test analyses the expression of genes in cancer cells from prostate tissue and which in combination with an advanced algorithm and data analysis provides decision support for optimal treatment of individual patients when prostate cancer has been confirmed. Using AI (artificial intelligence) technology, the Prostatype Genomics genetic test makes it possible to better predict prostate cancer and categorize the patient's condition into different types of risk. In this way, the test can reduce the risk of overtreatment or undertreatment, which in many cases leads to major problems for the patient.

Prostatype® is currently the only genetic test for prostate cancer available in kit format.

The product is scalable in volume thanks to the algorithm on which the test is based.

Vision

Our vision is that doctors and patients after being diagnosed with prostate cancer should have full confidence in their treatment decisions.

Mission

Prostatype Genomics' mission is to make a difference in the lives of patients suffering from prostate cancer through the development and commercialization of transformative tests that guide treatment decisions. In this way, we can improve the quality of life and peace of mind for patients and at the same time reduce healthcare costs. Prostatype Genomics will achieve this by making Prostatype® the globally preferred test system for newly diagnosed patients with prostate cancer.

Table of Content

Page

A word from our CEO

Over the past year, Prostatype Genomics has continued to focus on our primary goals of commercializing Prostatype® in Europe and continuing to strengthen our scientific footprint. As healthcare, in the wake of the pandemic, has reopened for visits, we have increasingly been able to meet with doctors and decision-makers, and in all markets we are active in, the response has been very positive.

Successful validation studies in several markets

During last year and the first quarter of 2023, we have received acceptance from more than 100 urologists/urology clinics to start their own smaller local evaluations of Prostatype®, where around 20 clinics in Sweden, Germany, Spain and Italy have already completed the process. Some 30 units are currently in the middle of the validation phase, which is often required from a regulatory perspective, but is also a commercial prerequisite for being able to establish a new innovative product like Prostatype on the market. Of the clinics that have completed their evaluation, all units have decided to implement Prostatype in clinical routine, which shows the clinical need Prostatype® meets. In Sweden alone, 13 clinics currently offer Prostatype® to their patients after completed validations. If you want to see what they are, go to https://prostatype.se/contact/ for more information. More clinics both in Sweden and internationally are added continuously, which will contribute to continued sales growth.
These concrete steps forward naturally add energy and lessons to the organization where we continue to focus on further expanding our customer base both in Sweden and internationally.

Scientific publications

We recently had two scientific studies published in The Prostate, a leading peer-reviewed scientific journal aimed at urologists and oncologists. This significantly strengthens our scientific footprint while giving us a lot of exposure to our most important customer groups. Further validation studies are already underway or in the final phase of the planning stage, so additional data will be published in various scientific journals in the not-too-distant future, further increasing the value of Prostatype Genomics.

Exciting news in the US

In addition to the exciting development in our key European markets, our important investment in the US is accelerating. In January 2023, Steve Gaal was recruited to the role of CEO of our US commercial company, and shortly we will also hire a Chief Medical Officer (CMO) who will be based in the US. Having a respected physician as CMO is instrumental in leading the studies required for entry into the U.S. market. In order for these studies to be completed quickly and efficiently, while acting as a scientific and commercial door opener, we have chosen to collaborate with leading healthcare facilities and physicians. Shortly, we will be able to present exciting news with more details about these collaborations that will put Prostatype Genomics on the map even more clearly. It is also gratifying to announce that in June we have been invited to a meeting with Medicare, the single most important player in the United States, to discuss the introduction of Prostatype in the American reimbursement system.

Another important area we are in full swing with right now is to identify which laboratory partner with a so-called CLIA approval we want to collaborate with in the US market. At the time of writing, we have a number of interesting possible opportunities that are now being carefully evaluated with both short- and long-term aspects in mind. Once it is in place, we can initiate sales of Prostatype® on the US market without having to wait for FDA approval.

Leaving aside the sheer size of the US market, the use and substitution of prognostic biomarkers is very well established in the US. The fact that prognostic biomarkers are included in national guidelines and are reimbursed by Medicare and most insurance companies means that the conditions for a rapid establishment in the United States are very promising. Please read what Steven Gaal writes about the US market on the next page.

> "Of the clinics that have completed their evaluation, all units have decided to implement Prostatype in clinical routine, which shows the clinical need Prostatype® meets"

As you can see, we maintain a very high pace both scientifically and commercially, and the proceeds from our recently completed rights issue will be used exclusively for continued investments in the commercial and scientific business to continue to meet the milestones we have identified on the continued journey.

With this, I wish both existing owners and new investors a warm welcome to join Prostatype Genomics' continued exciting journey!

Fredrik Persson
CEO

Interview with Steven Gaal

Since we started launching Prostatype® in the US, we have received specific questions about the US market and what makes it special. Here we give Steven Gaal, President US operations, the opportunity to respond directly.

The US market is interesting for Prostatype Genomics. Beyond size, why is it so important?

There is a significant trend in the United States to use active monitoring in men with low-risk prostate cancer, to reduce the risks of overtreatment. A recent study published in JAMA (March 2023) reported that the use of active monitoring in low-risk men increased sharply, from 26.5% in 2014 to 59.6% in 2021, with an overall target of around 80%.

Prostatype® provides the solution required to help confidently achieve this goal through improved classification of men diagnosed with prostate cancer. Prostatype's P-score provides a robust and reproducible result that can help reduce differences in the extent to which urologists use active monitoring. Improved stratification of patients through P-score enables better treatment outcomes, lower costs and higher quality of life for men diagnosed with prostate cancer, and that active monitoring is used on more men.

What does the US launch plan look like?

Prostatype Genomics' transformation strategy for the United States is diverse with different components being developed in parallel. Importantly, we have initiated the process of obtaining reimbursement from Medicare, which provides financial coverage for a significant portion of men diagnosed with prostate cancer and is the basis for a commercial reimbursement. In addition, it is important to establish laboratory services with CLIA certification and CAP accreditation to provide the level of service that patients and doctors require.

Recruitment of a globally recognized and reputable Chief Medical Officer has begun. This will provide medical guidance to ensure that the test is used correctly in the clinics, as well as to develop further important studies with Prostatype®.

We have also finally started our marketing efforts in the US, introducing the test to American urologists and pathologists. Prostatype Genomics is investing heavily in reaching out to medical decision-makers during the annual meeting of the American Urological Association (AUA) April 28-30, 2023. I look forward to coming back with a report on this!

Steven Gaal
President, US Operations

Annual Report

Prostatype Genomics AB 556726-0285

Financial Year

2022-01-01 - 2022-12-31

Administration Report

The Board of Directors and the CEO of Prostatype Genomics AB, 556726-0285, with its registered office in Stockholm, hereby submit the annual report for the financial year 2022-01-01 – 2022-12-31.

General information about the business

Prostatype Genomics' business concept is to develop prognostic methods against cancer. The first project concerns Prostatype, a product for the classification of prostate cancer, which is the most common cancer among men in many countries, in particular all in Western Europe and North America. There are currently no good methods that can determine the aggressiveness of prostate cancer.

This creates problems when choosing a treatment that is specifically tailored to the individual patient's needs.

About 10,000 men in Sweden and 500,000 in Europe are diagnosed with prostate cancer annually. Most people, about 65 percent, have a slowlygrowing cancer and the risk is small that the disease will become really serious in ten to fifteen years' time. Methods used today for diagnosis and prognosis are serum PSA, assessment of tissue samples from the prostate according to the Gleason Score and other clinical assessments. These methods are not sufficient to be able to assess the future development of the tumour in the early stages of the disease in the individual patient. Since the prognosis methods used today are uncertain, men with slowly growing cancer risk being unnecessarily treated with radical methods such as prostatectomy and/or radiotherapy, which often leads to side effects such as urine leakage, impotence and gastrointestinal problems, which in turn leads to reduced quality of life for the individual patient.

A method that can determine a tumor's development in direct relation to treatment choices provides the opportunities to individualize treatment according to the patient's needs. A classification of patients' prognosis also lowers healthcare costs by limiting resource-intensive treatments to patients whose tumour disease has a more negative prognosis.
The company has granted patents for Prostatype® in Europe, Japan, Hong Kong, Canada, China and the US.

Major owners

The largest shareholder in Prostatype Genomics AB is Creathor Venture with approximately 16.9% of the votes. JDS Invest AB is the second largest shareholder with a holding amounting to approximately 4.7% of the total number of votes.

Significant events during the financial year

Strengthened commercial organization

Prostatype Genomics continues to strengthen the European sales organization and has hired Albin Bremer as Sales Manager responsible for the Nordic market. Albin has over 20 years of experience from both sales and sales manager roles in several leading pharmaceutical companies such as Abbott and ALK-Abelló. Most recently, Albin comes from Ipsen where he was involved in starting up and developing the company's oncology division with a strong commercial focus.

Enhanced accessibility for laboratories

Together with Karolinska Institutet in Stockholm, Prostatype Genomics has carried out an extensive validation process with the aim of greatly increasing the availability of Prostatype®. By validating laboratory kits from more suppliers and several instruments for RNA amplification, many more laboratories can now perform the test when the results of the validations have been positive.

Strong results for Prostatype® in Asian pilot study

The latest study was conducted in China in collaboration with Nanjing Drum Tower University Hospital, Jiangsu, and Prostatype Genomics partner GloriousMed based in Shanghai. The study indicates that the clinical performance of Prostatype® in East Asian populations is in line with the results previously demonstrated in several studies in Caucasian populations. A total of 108 patients were included in the pilot study. All patients who either died of prostate cancer or developed metastases were identified as "high-risk" patients according to the Prostatype® P-score. The study was selected for presentation at the Chinese Urology Association's National Congress.

Outcome of completed rights issue of units

On July 20 2022, the Company's rights issue of units was completed. The rights issue was subscribed for a total of approximately SEK 17.9 million, including subscription commitments of approximately

SEK 8.5 million, corresponding to a subscription rate of approximately 79.5 percent. In addition, guarantee commitments corresponding to approximately SEK 4.6 million have been activated, which means that Prostatype Genomics will receive 100 percent of the issue volume. Prostatype Genomics will thereby receive approximately SEK 22.5 million before issue costs of approximately SEK 3.1 million in total (including guarantee compensation of approximately SEK 1.4 million). Through the rights issue, a total of 7,755,895 shares and 7,755,895 warrants of series TO 2 are thus issued. A total of 306,315 units (corresponding to approximately SEK 16.9 million) were subscribed for with the support of unit rights, including subscription commitments of approximately SEK 8.5 million. Allotment of units has been made in accordance with the allotment principles described in the prospectus published by the Company in connection with med the rights issue.

Rights issue

In May 2022, the Board of Directors announced in connection with the notice convening the Annual General Meeting that it was seeking authorization for a rights issue (the "Rights Issue") of units initially of approximately SEK 22.5 million before issue costs, followed by an additional approximately SEK 22.5 million before issue costs attributable to associated warrants. The Annual General Meeting granted the authorization and in June the Board of Directors resolved to carry out the Rights Issue.

Collaboration with Capio Solna Urologi

In April, the Company announced that it has initiated a collaboration with Capio Solna Urologi and that the first patient has been treated based on prognostic test results from the use of Prostatype®.

First order to the UK

In March, the Company announced that Cambridge Clinical Laboratories (CCL), Prostatype Genomics' partner in the UK and Ireland, has placed the first order for the Company's gene test, Prostatype®. This means that Prostatype Genomics has taken another step in the commercialization process in yet another prioritized market.

Establishes subsidiary in the US

In March, Prostatype Genomics announced that the Company is establishing a subsidiary in the US, Prostatype Genomics, Inc., wholly owned 100% of Prostatype Genomics AB. The establishment of the subsidiary is an important step in the work towards the US market entry.

Exercise period for Prostatype Genomics warrants of series TO 1 begins

On January 27, 2022, the exercise period for the warrants of series TO 1 issued in connection with Prostatype Genomics' issue of units in September 2020 began. The useful life lasted until February 17, 2022.

Outcome in option redemption

On February 17, 2022, the exercise period for Prostatype Genomics' warrants of series TO 1, which were issued in connection with the Company's issue of units in September 2020, ended. A total of 14,841 warrants of series TO 1 were exercised.

Presentation under American Urology Association Annual Meeting

In January, the Company announced that the results of the study conducted by Uppsala University Hospital have been selected for presentation at AUA, American Urology Association Annual Meeting 2022, one of the largest and most important gatherings for urologists in the world, which takes place in New Orleans on May 13-16. It is an important step in the upcoming launch of Prostatype® in the US market.

Events after the end of the period

Rights issue and extraordinary general meeting

To ensure the Company's continued operation and execution of its business plan, the Board of Directors decided in March 2023 to propose a rights issue. At an extraordinary general meeting on April 21, 2023, the Board of Directors' proposal was approved and it was resolved to carry out a rights issue. (See under the Funding section below.)

Outcome of TeckningsOptioner Series TO 2

During the period 9-30 March 2023, holders of warrants of series TO 2 have had the right to subscribe for shares with the support of warrants. One (1) warrant of series TO 2 entitles the holder to subscribe for one (1) new

share in Prostatype Genomics at a subscription price set at SEK 2.90. A total of 2,622 warrants of series TO 2 have been exercised, corresponding to a subscription of SEK 7,603.80. The utilization entails a dilution of 0.01 percent. Conversion from interim shares to ordinary shares is expected to take place around 19 April 2023 and ordinary shares was visible on each subscriber's custody account approximately two banking days thereafter.

Collaboration with Spanish Eurofins Megalab

Prostatype Genomics initiates collaboration with Eurofins Megalab, a leader in clinical analysis in the Spanish laboratory market and part of Eurofins, one of the world's largest laboratory groups with operations in Europe, the US, Asia and Latin America. The agreement means that Eurofins Megalab will handle all steps of the laboratory process required to analyze the Prostatype® test on the Spanish and Portuguese markets. The collaboration is another step in Prostatype Genomics' work to further accelerate commercialization in Europe. The agreement will enter into force immediately.

Study with Prostatype® published in leading international journal

The study, conducted by a research team at Uppsala University Hospital led by associate professor and chief physician Michael Häggman, shows that the Prostatype® gene test correctly assesses the aggressiveness of the prostate cancer tumor when comparing gene expression from tissue samples, so-called biopsies, with the "result", i.e. the operated prostate (radical prostatectomy). The study is now published in The Prostate, a leading peer reviewed publication aimed at, among others, urologists and pathologists.

Prostatype Genomics recruits Steven Gaal as President of Prostatype Genomics Inc., USA

Prostatype Genomics AB has recruited Steven Gaal to the role of President of the company's wholly owned subsidiary, Prostatype Genomics Inc. Stevens' task will be to establish and launch Prostatype®, the company's gene test for assessing the aggressiveness of prostate cancer in patients, on the US market. Steve has over 18 years of experience from leadership positions in sales of cancer diagnostic tools and services and will join Prostatype Genomics Inc. with immediate effect. Steven joins Prostatype Genomics Inc. with extensive experience in genomic testing. Steven has experience working in both start-ups and more established companies. He has held senior positions at USLABS (acquired by LabCorp), P4Diagnostix and most recently SkylineDx. As Sales Director at MDxHealth, Steven was instrumental in launching ConfirmMDx for prostate cancer and SelectMDx for prostate cancer to US-based urologists.

Prostatype Genomics AB enters into agreement with Life Genomics AB

Prostatype Genomics and Life Genomics are entering into a non-exclusive collaboration whereby Life Genomics will handle all steps in the laboratory process required to analyze Prostatype, the Prostatype® Genomics gene test to assess the aggressiveness of prostate cancer. The collaboration means that Prostatype Genomics can further focus on marketing the test to patients and doctors and secures resources to be able to handle the increased demand for Prostatype® from patients and healthcare. The agreement applies to all Nordic countries and enters into force immediately.

The collaboration means that Life Genomics will handle the entire process from receiving referrals from healthcare providers to performing and reporting the results of the gene analysis in accordance with Prostatype Genomics' quality-assured processes.

Profit for the year

The company made a negative profit of SEK 29,087 thousand during the financial year . During the period, the Company was still in the phase of initial commercialization of the Company's product Prostatype®. The productis considered to be fully developed.

Development of company operations, result and position

Amounts in TSEK	2022-12-31	2021-12-31	2020-12-31	2019-06-30	2018-06-30
Net sales	683	10	684	74	162
Balance Sheet Total	30 950	40 203	33 663	17 574	19 711
Net Result after financial items	-29 087	-15 630	-17 408	-8 546	-9 318
Equity ratio %	84	89	84	49	32

Financing

in November 2020. A total of 3,885,320 units (shares with attached warrants) were subscribed for. Initially, the company thus received gross SEK 37.5 million in equity. After deduction of issue expenses, compensation to convertible bondholders and bridge loan financiers, the company's net equity was provided with approximately SEK 31.5 million. The cash injection amounted to a net SEK 15.8 million after deduction of issue expenses and set-off of convertibles and bridge loans. On February 17, 2022, the exercise period for the Company's warrants of series TO 1, which were issued in connection with the Company's issue of units in September 2020, ended. A total of 14,841 warrants of series TO 1 were exercised. Through the utilization, the Company thereby received a total of approximately SEK 162 thousand before issue costs.

In June 2022, the Annual General Meeting resolved to carry out a rights issue of units that ended onJuly 20. The rights issue was subscribed for a total of approximately SEK 17.9 million, including subscription commitments of approximately SEK 8.5 million, corresponding to a subscription rate of approximately 79.5 percent. In addition, the guaranteed commitments corresponding to approximately SEK 4.6 million have been activated, which means that Prostatype Genomicsreceived 100 percent of the issue volume. Prostatype Genomicsthereby received approximately SEK 22.5 million before issue costs of a total of approximately SEK 3.1 million (including guarantee compensation of approximately SEK 1.4 million). Through the rights issue, a total of 7,755,895 shares and 7,755,895 warrants of series TO 2 were thus issued. A total of 306,315 units (corresponding to approximately SEK 16.9 million) were subscribed for with the support of unit rights, including subscription commitments of approximately SEK 8.5 million. Allotment of units has been made in accordance with the allotment principles described in the prospectus published by the Company in connection with the rights issue. On March 30, 2023, the exercise period for the Company's warrants of series TO 2 issued in connection with the Company's issue of units in July 2022 ended. A total of 2,622 warrants of Series TO 2 were exercised. Through the utilization, the Company received a total of approximately SEK 8 thousand before issue costs.

To ensure the Company's continued operation and execution of its business plan, the Board of Directors decided in March 2023 to propose a rights issue. At an extraordinary general meeting on April 21, 2023, the Board of Directors' proposal was approved, and it was resolved to:

- One (1) existing share in Prostatype Genomics held on the record date, April 25, 2023, entitles to one (1) subscription right. One (1) subscription right entitles to subscription of six (6) newly issued shares.
- The subscription price amounts to SEK 0.25 per share. Payment must be made in cash.
- Through the rights issue, Prostatype Genomics can raise a maximum of approximately SEK 34.3 million before issue costs, which are estimated to amount to approximately SEK 2.8 million.
- The subscription period runs from April 27 to May 11, 2023.
- Subscription rights that are not exercised during the subscription period become invalid and lose their value. Trading in subscription rights is planned to take place on Nasdaq Premier First North Growth Market during the period 27 April – 8 May 2023.
- Upon full subscription, the rights issue means that the Company's share capital increases by a maximum of SEK 8,229,418.92, corresponding to a maximum of 137,156,982 shares and a maximum dilution of 85.7 percent.
- The rights issue is secured to 70 percent through subscription commitments and guarantee undertakings from existing and external investors.
- To enable the rights issue, the Annual General Meeting resolved to amend the Articles of Association's limits for share capital and number of shares in accordance with the Board's proposal. The new wording is as follows.

§ 4 Share capital

The share capital shall be not less than SEK 6,000,000 and not more than SEK 24,000,000.

§ 5 Number of shares

The number of shares shall be not less than 100,000,000 and not more than 400,000,000.

The AGM also resolved to approve the Board of Directors' proposal to, on one or more occasions during the period until the next Annual General Meeting, resolve to increase the company's share capital within the limits of the Articles of Association. The authorization may only be used to issue shares to those who acted as guarantors in the above-mentioned issue. All resolutions at the Annual General Meeting were passed unanimously.

Market and operational risks

Market acceptance

The company's product, Prostatype®, is in a commercialization phase. At the date of this prospectus, sales of Prosta-type® have been initiated in Sweden, Germany, Spain, the UK and Italy and going forward the Company aims to launch the product in the US. However, there is a risk that the sale does not fully meet the Company's objectives and that the product will not be commercially successful. The level of market acceptance and sales of Prostatype® depends largely on whether the product succeeds in gaining recognition among urologists, but also on a number of other factors, such as product characteristics, clinical documentation and results, competing products, distribution channels, availability, price, compensation, sales and marketing efforts and that the product is mentioned and noticed in various trade journals. If the Company and its product do not receive sufficient attention in the right channels, there is a risk of causing delays in the market acceptance of Prostatype® or that such a total or partial failure to occur.

Since Prostatype® has not yet generated any significant revenue, it is difficult to evaluate the sales potential of the product. The product is a support in healthcare choices for the treatment of prostate cancer and aims to avoid unnecessary operations. The company intends to initially conduct sales to private healthcare (private hospitals, insurance companies and out-of-pocket patients). To achieve the market penetration required to achieve the Company's financial targets, a small number of urologists in the target group need to be convinced. The company considers this to be a realistic expectation. In public healthcare, it takes longer to reach acceptance and the Company will be dependent on the national reimbursement systems. The risk is therefore considered to be low in relation to private healthcare and medium in public healthcare. A certain conflict of interest can be considered to exist between private healthcare providers' willingness to perform surgeries and the Company's ambition to avoid unnecessary ones, which risks affecting market acceptance.

Medical technology is generally a market area characterized by global competition, rapid technological development, regulatory requirements, and extensive investment requirements. Prostatype Genomics estimates that there is currently no product on the European market that fully corresponds to Prostatype®, but that there are companies in medical technology that may become potential competitors to Prostatype Genomics, e.g., by these companies developing an equivalent product. Should competitors develop products that prove to be better than the Company's, it could have a material adverse effect on the Company's business, sales, market acceptance, financial position and results of operations as other Companies may take market shares. The competitive situation in the US market is different as there are a few US companies that manufacture products comparable to Prostatype®. In the US market, the Company may thus be exposed to competition from existing competitors who want to prevent or complicate the marketing of Prostatype® in various ways, e.g., by challenging the Company's patents.

Overall, Prostatype Genomics estimates that the probability of the risk occurring is medium. The Company further assesses that the risk, if realized, would have a high effect on the Company.

Dependence on key personnel

Prostatype Genomics is a small organization that currently has eight employees. The Company's success is largely dependent on qualified labour and on the extensive competence and long experience in the Company's field of activity held by the employees. Due to the size of the organization and each employee's experience in the business area, each employee is considered a key person on whom the Company's operations depend in various respects. One of the Company's main strengths is the internal knowledge of advanced laboratory technology, AI technology and data analysis, which is partly linked to the Company's personnel. Particularly central to day-to-day operations is also that the CEO and CFO's commitment to the Company continues. If several key employees were to leave within a short period of time, it would have a significant negative effect on the Company's ability to conduct the business and achieve the results the Company seeks. It could also delay the Company's operations and negatively affect its ability to achieve commercial goals.

Prostatype Genomics assesses the probability of occurrence of the risk as low. The Company further assesses that the risk, if realized, would have a high effect on the Company.

Future financing needs

The Company has been loss-making since the Company was formed. These losses have arisen primarily from research and development costs, studies and from general and administrative expenses in

connection with the Company's operations. The Company is in an establishment phase where expected cash flows from the Company's operating activities do not cover planned costs and investments in the form of launching in new markets. Additional financing in the form of loans or other external financing may be needed to finance the working capital requirement. There is a risk that the Company cannot raise additional capital or that such financing cannot be obtained on, for existing shareholders, favorable terms. This may mean that the commercialization of Prostatype® is slowed down and that the Company is forced to conduct operations at a slower pace than desired, which may lead to delayed or lost revenue. It may also be significant for the Company's establishment in the US because of the financing needs that exist from that business. The scenario could have a negative impact on the Company's operations, financial position, and results of operations.

Prostatype Genomics assesses the probability of risk occurring as medium. The Company further assesses that the risk, if realized, would have a medium effect on the Company.

Legal and regulatory risks

Regulatory risks associated with studies and permits

Before medical devices, such as Prostatype, can be launched on the market, their performance and safety must be ensured, which Prostatype® Genomics has done through clinical studies as well as validation studies in several countries. Prostatype Genomics' strategy is to conduct validation studies in each country where sales are intended to be conducted, which does not follow from regulatory requirements but rather from practice. In order to be able to market and sell medical devices, in some cases a permit must also be obtained, and registration must take place with the relevant authority. Prostatype® is CE-marked and the Company has at the date of this prospectus permission to sell the product in Europe. The company has conducted a validation study in China and has an ongoing validation study in Taiwan to evaluate the launch of Prostatype® on the Asian market. In the US, the Company has no ambition to secure FDA approval, but seeks collaborations with laboratory partners who already hold so-called CLIA accreditation, which shortens the time to market launch and reduces financial risk. Currently, the Company intends to invest in a validation study for market launch in the US and new validation studies in Sweden.

The studies conducted by Prostatype Genomics are associated with uncertainty and risk regarding delays and results. There is a risk that results in the Company's ongoing and future studies will not be satisfactory and there is a risk that the Company's future products for safety and/or efficiency reasons will not be demonstrated to be as good as previously estimated. Furthermore, there is a risk that the rules and interpretations that currently apply regarding registration and permits for the Company's product may change in the future, which in that case could affect the Company's ability to meet the requirements of various authorities. Thus, changes in rules and interpretations as well as revoked permits and registrations may also cause delays in market launches in certain markets and risk reducing the Company's growth rate and expected profitability. All in all, it could have a negative impact on the Company's business, financial position and results.

Prostatype Genomics assesses the probability of occurrence of the risk as low. The Company further assesses that the risk, if realized, would have a medium effect on the Company.

Intellectual property rights and patent protection as well as infringement thereof Prostatype Genomics depend on the ability to obtain and defend patents, other intellectual property rights and reprocessed know-how. Patent protection for medical device companies can be uncertain and cover complex legal and technical issues. Prostatype Genomics has applied for and been granted patents until 2032 in the US, Canada, China, Hong Kong, Japan and Europe (EPO). In the event that future patent applications are not granted, it could adversely affect Prostatype Genomics' operations and financial position. Furthermore, patents usually have to be applied for and maintained in several different jurisdictions and generally have a limited lifespan. There is a risk that existing and/or future patent portfolio and other intellectual property rights held by the Company will not constitute adequate commercial protection, that other patent(s) dominate over your own patent(s) or that methods or procedures that are patented or patent pending by others will be used. If Prostatype Genomics is forced to defend its patent rights against a competitor, this may entail significant costs, which may adversely affect Prostatype Genomics' business, results and financial position. Furthermore, there is always a risk in the type of business that Prosta-type Genomics conducts that the Company may make or is alleged to infringe patents held by third parties. To date, the Company has not been involved in any patent dispute. Nor can it be ruled out that new patents in the field or new discoveries may affect.

Equity

SEK	Share Capital	Development fund	Share premium reserve	Accumulated profit/loss
Opening balance	905 325	18 566 363	130 452 900	-114 018 748
New share issue		-1 856 636		1 856 636
Expenses of the issue	466 244		22 104 639	
Transfer to development fund			-3 239 158	
Annual result				-29 086 533
Closing balance	**1 371 569**	**16 709 727**	**149 318 381**	**-141 248 645**

Number of shares

On December 31st, 2022, the number of shares was 22 859 497.

Outstanding options program

At an Extraordinary General Meeting in June 2020, it was decided on two option programs for management and personnel and for the Board members, respectively. As of the date of this annual report, a total of 159,871 options were subscribed, of which 41,856 were for board members who provide the opportunity to subscribe for one share. for each option, in August 2023, at a price of SEK 13.51.

Proposed allocation

The Board of Directors proposes that the accumulated equity of SEK 8 069 738, is accommodated as follows:

Amount in SEK	
Accumulated loss	37 156 269
Loss of the year	-29 086 533
Total	**8 069 738**
Carried forward	8 069 738
Total	**8 069 738**

Regarding the results and position in general, reference is made to the subsequent results, balance sheet and cash flow statement with the associated notes.

Income Statement

(SEK)		2022-01-01 2022-12-31	2021-01-01 2021-12-31
	Not		
Net sales		682 798	10 001
Own work capitalized		-	2 499 641
Other operationg income	2	-	12 186
Total revenue		**682 798**	**2 521 828**
Operating expences			
Research and development cost		-3 507 690	-1 488 110
Other external costs	4	-13 488 884	-8 491 058
Staff cost	5	-10 388 148	-7 980 680
Depreciation, amortization and impairment	6,7	-1 904 302	-88 483
Other operating expenses		-84 067	-21 762
Operating profit/loss		**-28 690 293**	**-15 548 265**
Income after financial items			
Interest and similar items		-396 240	-81 493
Profit/loss after financial items		- 29 086 533	-15 629 758
Profit or loss before tax		-29 086 533	-15 629 758
Total profit/loss for the period		**-29 086 533**	**-15 629 758**

Balance Sheet

(SEK)		2022-12-31	2021-12-31
Assets	**Not**		
Fixed assets			
Intangible assets			
Capitalized development expenditure	6	16 709 726	18 566 363
Patent	7	-	37 175
Total intangible assets		**16 709 726**	**18 603 538**
Property, plant and equipment			
Plant and machinery	8	-	-
Equipment and tools	9	3 599	14 089
Total property, plant and equipment		**3 599**	**14 089**
Financial assets			
Other financial assets		68 136	-
Total financial assets		**68 136**	
Total fixed assets		**16 781 461**	**18 617 627**
Current assets			
Inventory			
Finished products		43 800	107 520
Advances to suppliers		138 486	74 506
Total current assets		**182 286**	**182 026**
Current receivables			
Accounts receivable		502 434	146 573
Other receivables		1 655 830	502 980
Prepaid expenses and accrued income		339 464	424 429
Total current receivables		**2 497 728**	**1 073 982**
Short-term investments			
Other short-term investments		6 677 581	10 500 000
Total short-term investments		**6 677 581**	**10 500 000**
Cash and bank		**4 811 151**	**9 829 175**
Total current assets		**14 168 746**	**21 585 183**
Total assets		**30 950 207**	**40 202 810**

(SEK)		2022-12-31	2021-12-31
Equity and liabilities			
Total equity			
Restricted equity			
Share capital	10,15	1 371 569	905 326
Development fund		16 709 726	18 566 363
Total restrictred equity		**18 081 295**	**19 471 689**
Non-restricted equity			
Share premium reserve		149 318 381	130 452 900
Profit/loss brought forward		-112 162 111	-98 388 990
Net profit/loss for the year		-29 086 533	-15 629 758
Total non-restricted equity		**8 069 738**	**16 434 152**
Total equity		**26 151 033**	**35 905 840**
Long-term liabilities			
Convertible loan			-
Other debt to credit institutions	11,14	466 667	866 667
Total long-term liabilities		**466 667**	**866 667**
Current liabilities			
Debt to credit institutions	12,14	400 000	400 000
Accounts payable		**2 183 975**	**1 174 708**
Tax liabilities		**240 286**	**176 876**
Other current liabilities		461 364	212 175
Accrued liabilites and deferred income	13	1 046 881	1 466 544
Total current assets		**4 332 506**	**3 430 303**
Total equity and liabilites		**30 950 207**	**40 202 810**

Cash Flow Analysis

(SEK)	2022-01-01 2022-12-31	2021-01-01 2021-12-31
Operating activities		
Profit after financial items	-29 086 533	-15 629 758
Adjustments for items not included in cash flow etc	1 904 302	88 483
Cash flow from operationg activities before changes in working capital	**-27 182 231**	**-15 541 275**
Cash flow from changes in working capital		
Change in inventory	-260	212 921
Change in operating receivables	-1 423 746	125 480
Change in operating liabilities	912 855	-875 336
Cash flow from current operations	**-27 693 382**	**-16 078 210**
Investment activities		
Acquistion of intangibles	-	-2 499 641
Acquisition of fixed assets	-	-
Cash flow from investment activities		**-2 499 641**
Financing activites		
Paid-in option premium	-	-
Net issue liquitidy incl. bridge loan	19 252 938	23 245 239
Recieved convertible loans	-	-
Amortization	-400 000	-200 000
Cash flow from financing activities	**18 852 939**	**23 045 239**
Cash flow for the period	**-8 840 443**	**4 467 388**
Cash equivalents at the beginning of the period	**20 329 175**	**15 861 788**
Cash equivalents at the end of the period	**11 488 732**	**20 329 175**

Notes

Not 1 Accounting principles

Amounts in TSEK unless otherwise stated.

General accounting principles

The annual report has been prepared in accordance with the Annual Accounts Act and the Accounting Standards Board's general guidelines BFNAR 2012:1 Annual and Group Reports (K3).

Valuation principles etc

Assets, provisions and liabilities are valued based on cost unless otherwise stated.

Foreign currency

Monetary entries in foreign currencies are calculated to exchange rates on the balance-sheet day. Non-monetary entries are not recalculated but are reported to the exchange rate at the time of acquisition.

Inventories

Inventories are reported at the lower of cost and net realisable value. This takes the risk of obsolescence into account. The acquisition value is calculated according to the first-in first-out principle

Employee compensation

The description below gives an example of the conditions that may exist. The description of accounting principles must be adapted and revised based on applied plans and conditions.

Compensation to employees after terminated employment

Classification

Plans for compensation after termination of employment classified as either defined contribution or defined benefit. In the case of fixed-fee plans, it is paid fixed fees to another company, normally one insurance company, and no longer has any obligation to the employee when the fee is paid. The size of it employee compensation after termination of employment is depending on the fees that have paid and the return on capital that the fees provide.

Defined contribution plans

Plans for compensation after terminated employment are classified as either defined contribution or defined benefit. For defined contribution, fixed fees are paid to another company, normally an insurance company, and no longer have any obligations to the employee once the fee has been paid. The size of the employee compensation after terminated employment is dependent on the fees that have been paid and the return on capital of the fees.

For defined benefit, the company has an obligation to give the agreed compensations to present and earlier employees. The company substantially bears partly the risk that the compensation payments are higher than expected (actuarial risk), partly the risk that dividends on the assets deviate from those expected (investment risk). There is also an investment risk if the assets are transferred to another company.

Miscellaneous long-term compensation to employees
Liabilities with respect to long-term compensations to employees are reported to current value of the obligation on the balance sheet day.

Compensations for dismissal

Compensations for dismissal, provided the compensation does not give the company future financial benefits, are reported only as a liability and cost when the company has a legal or informal obligation to either
a) dismiss an employee or group of employees before the normal point in time for cessation of the employment, or
b) pay compensation for dismissal by making an offer for voluntary redundancy.

Compensations for dismissal are reported only when the company has a detailed plan for dismissals and does not have any realistic possibility of annulling the plan.

Tax

Tax on profits for the year in the Profit and Loss Account comprises current tax and deferred tax. Current tax is tax on income for the present financial year relating to taxable income and part of previous financial years' tax on income that has not yet been reported. Deferred tax is tax on income for taxable profits relating to future financial years as a result of past transactions or events. Deferred tax liability is reported for all taxable temporary differences but not for temporary differences arising from first reporting of goodwill.

Deferred tax assets are reported for deductible temporary differences and for the possibility of using fiscal deficit deductions in future. The valuation is based on how the reported value for the corresponding asset or liability 19 PROSTATYPE GENOMICS AB 556726-0285 is expected to be recovered or settled. The sums are based on the tax rates and fiscal regulations that are approved

prior to the balance sheet day and have not been present value computed.

Revenue

The influx of financial benefits that the company received or will receive for its own account is reported as income. Revenues are valued as the fair value of that received or to be received with deduction for discounts offered.

Sale of goods

Revenue from the sale of goods is recognized when the following criteria are met:

- The financial benefits that are coupled to the transaction will probably accrue to the company,
- The revenue can be calculated in a reliable manner,
- The company has transferred the significant risks and benefits coupled to the owner of the goods to the purchaser,
- The company has no longer such a commitment to the running management that is usually connected with the owner and does not either exert any real control over the sold goods, and
- The expenses that have arisen or are expected to arise because of the transaction can be calculated in a reliable manner.

Public contributions

A public contribution that is not associated with the demand for future performance is reported as an income when the conditions for the contribution are met. A public contribution that is associated with the demand for future performance is reported as an income when the requirements for the performance are fulfilled. If the contribution has been received before the conditions for reporting it as an income have been met, the contribution is reported as a liability

Intangible assets

Research and development expenses

The activation model is applied in case of capitalizing the expenses for development. This means that expenses incurred during the development phase are reported as an asset when all of the following conditions are met:

- It is technically possible to complete the intangible fixed asset so that it can be used or sold.
- It is intended to complete the intangible fixed asset and use or sell it.
- Prerequisites exist to use or sell the intangible fixed asset.
- It is probable that the intangible fixed asset will generate future financial benefits.
- Necessary and adequate technical, financial and other resources exist to finalize the development and to use or sell the intangible fixed asset.
- The expenses relating to the intangible fixed asset can be calculated in a reliable manner. The acquisition value of an internally generated intangible fixed asset consists of all directly attributable expenses (eg materials and salaries). Depreciation will begin when the product is completed.

The acquisition value of an internally processed intangible Fixed assets consist of all directly attributable asset expenses (e.g., materials and wages).

Depreciation has begun during the financial year.
The economic life is estimated at 10 years.

Other intangible fixed assets

Other intangible assets acquired by the company are recorded at acquisition value less accumulated depreciation and write-downs. Depreciation is made on a straight-line basis over the estimated useful life.

Costs for patent

External costs for patent applications in new markets are capitalized if the company is deemed to have a financial benefit from the patent in the relevant market. Amortization of capitalized patent costs will take place during the useful life from the time this starts. If the asset on the balance sheet date has a lower value than the book value, the asset is written down to this lower value.

Tangible assets

Tangible fixed assets are reported to the cost of acquisition less accumulated depreciation and impairment [Or with addition for revaluations.] The acquisition value includes, in addition to the acquisition price, even expenses that are directly related to the acquisition.

Depreciation

Depreciation is linear over the estimated lifetime of the asset as this reflects the expected consumption of the asset's future financial benefit. Depreciation is reported as a cost in the Profit and Loss Account.

Tangible assets	Year
Machinery and other technical equipment	5
Equipment, tools and installations	5

Leasing

Leasing fees in accordance with operational leasing agreements, including the initial payment but excluding expenses for services such as insurance and maintenance, are reported as a cost linearly over the leasing period.

Not 2 Estimations and assessments

Prostatype Genomics AB makes estimates and assessments about the future. The estimates for accounting purposes that result from these will, by definition, rarely correspond to the actual result. The estimates and assumptions that involve a significant risk of significant adjustments in the reported values of assets and liabilities in the coming years are dealt with in outline below.

Deficit dediction

Prostatype Genomics AB's loss carryforward has not been valued and is not reported as a deferred tax asset. These loss carryforwards are valued only when the company has established a profit level which the company management with certainty considers will lead to tax surpluses.

Intangible assets

Management continuously assesses the value of the company's intangible fixed assets. Important assumptions for assessing whether a possible impairment need has arisen primarily consist of an assessment of future sales growth and operating margin. If an indication of impairment arises, an impairment test is performed. An impairment test has been performed, which does not indicate a need for impairment.

Until the company reaches a positive operating cash flow is the company thus dependent on external financing, in the first place hand through equity, to implement their business plan. Through the completed issue in 2022 as well as the new issue planning for 2023, the financing is assessed be secured.

Not 3 Other operating income

	2022-01-01 2022-12-31	2021-01-01 2021-12-31
Other	-	12 186
Total	**-**	**12 186**

Not 4 Remuneration and expenses of auditors

Grant Thornton Sweden AB	2022-01-01- 2022-12-31	2021-01-01- 2021-12-31
Audits assignments	339 059	211 530
Other assignments	75 680	106 515
Tax advice	0	0
Other services	0	0
Total	**414 739**	**318 045**

Auditing assignments refer to statutory audits of the annual accounts and the accounts, as well as the administration of the board and the managing director and auditing and other audits conducted in accordance with agreement or agreement. This includes other duties that it is the responsibility of the company's auditor to perform as well as advice or other assistance caused by observations in such review or peformance of such other duties.

Not 5 Employees and personnel costs

Average number of employees	2022-01-01- 2022-12-31	2021-01-01- 2021-12-31
Totalt	**6**	**5**

Salaries and other remunererations distributed between board members etc. and other employees	2022-01-01- 2022-12-31	2021-01-01- 2021-12-31
Salaries and other remunerations, the board of directors and CEO	2 290 000	2 850 501
Salaries and other remunerations, employees	4 671 958	2 634 679
Social costs	2 966 044	2 097 306
(Of which pension costs)		865 801
Total	**9 928 002**	**7 582 486**

Reporting of gender distributions in the company management		
Number of woman	20%	40%
Number of men	80%	60%
Proportion of women among other senior executives	0%	0%
Proportion of men among other senior executives	100%	100%
Total	**9 928 002**	**7 582 486**

The CEO has a notice period of six months and is entitled to six months' remuneration upon termination.

Not 6 Capitalised expenditure for development work and similar

Ackumulated costs of acquisitions	2022-12-31	2021-12-31
At beginning of year	18 566 363	16 066 722
Internally developted assets	0	2 499 641
Carrying amount at year-end	**18 566 363**	**18 566 363**

Accumulated depreciation	2022-12-31	2021-12-31
At beginning of year	-	-
Depreciation of thee year	-1 856 636	-
Carrying amount at year-end	**16 709 726**	**18 566 363**

Not 7 Concessions, patents, licenses, trademarks and similar rights

Accumulated costs of acquisitions	2022-12-31	2021-12-31
At beginning of year	371 756	371 756
At the end of the year	371 756	371 756

Accumulated depreciation	2022-12-31	2021-12-31
At beginning of year	-334 581	-260 229
Depreciation of the year	-37 175	-74 352
At the end of the year	-371 756	-334 581
Carrying amout at year-end	**-**	**37 175**

Not 8 Machinery and other technical equipment

Ackumulated costs of aquisitions	2022-12-31	2021-12-31
At beginning of year	487 990	487 990
Carrying amount at year-end	487 990	487 990

Accumulated depreciation	2022-12-31	2021-12-31
At beginning of year	-487 990	-487 990
Depreciation of the year	-	-
At the end of the year	-487 990	-487 990
Carrying amount at year-end	**-**	**-**

Not 9 Equipment, tools and installations

Ackumulated costs of aquisitions	2022-12-31	2021-12-31
At the beginning of the year	244 648	244 648
New aquisitions	-	-
Carrying amout at year-end	**244 648**	**244 648**

Ackumulated depreciation	2022-12-31	2021-12-31
At the beginning of the year	-230 559	-216 428
Depreciation of the year	-10 490	-14 131
	-241 049	-230 559
Carrying amout at year-end	**3 599**	**14 089**

Not 10 Number of shares

	2022-12-31	2021-12-31
Number of shares	22 859 497	15 088 761

Not 11 Long-term liabilities

Liabilities that fall due more than one year after the balance-sheet day	2022-12-31	2021-12-31
Growth loan, Almi	466 667	866 667
Carrying amount at year-end	**466 667**	**866 667**

Not 12 Short-term liabilities

Liabilities that fall due more than one year after the balance-sheet day	2022-12-31	2021-12-31
Growth loan, Almi	400 000	400 000
Carrying amount at year-end	**400 000**	**400 000**

Not 13 Accruals and prepaid income

	2022-12-31	2021-12-31
Accrued holiday pay	567 272	506 157
Accrued bonus	-	-
Estimated accrued social security contributions	178 237	159 034
Accrued board members fees including social security	123 206	174 107
Other interim debt	178 166	627 245
Carrying amount at year-end	**1 046 881**	**1 466 543**

Not 14 Pledged assets and cotingent liabilities

Securities pleadged	2022-12-31	2021-12-31
Chattel mortgages	3 500 000	3 500 000
Assets with ownership reservation	109 872	109 733
Total pledged assets	**3 609 872**	**3 609 733**

Contingent liabilities

According to the board's assessment, the company has none contingent liabilities.

Not 15 Number of shares

Number of shares	2022-12-31	2021-12-31
At beginning of year	15 088 761	13 186 870
Share issues	7 770 736	1 901 891
Total number of shares	**22 859 497**	**15 088 761**

Not 16 Transactions with related parties

During the period from January 1 2022 to 31 December 2022, except for what is detailed below, no related part transactions have taken place.

During the period January 2022 - December 2022, the company purchased services worth SEK 399 086 (1,008,002) from the company SecureAppbox AB, which delivers web-based solutions for P-scores. Prostatype Genomics AB's board member Håkan Englund is chairman of SecureAppbox. Håkan Englund has not been involved in the procurement of these services. Transactions with related parties have been performed on market terms.

Not 17 Significant events after the end of the financial year

Rights issue and extraordinary general meeting

To ensure the Company's continued operation and execution of its business plan, the Board of Directors decided in March 2023 to propose a rights issue. At an extraordinary general meeting on April 21, 2023, the Board of Directors' proposal was approved and it was resolved to:

1. One (1) existing share in Prostatype Genomics held on the record date, April 25, 2023, entitles to one (1) subscription right. One (1) subscription right entitles to subscription of six (6) newly issued shares.
2. The subscription price amounts to SEK 0.25 per share. Payment must be made in cash.
3. Through the rights issue, Prostatype Genomics can raise a maximum of approximately SEK 34.3 million before issue costs, which are estimated to amount to approximately SEK 2.8 million.
4. The subscription period runs from April 27 to May 11, 2023.

Subscription rights that are not exercised during the subscription period become invalid and lose their value. Trading in subscription rights is planned to take place on Nasdaq Premier First North Growth Market during the period 27 April – 8 May 2023.

Upon full subscription, the rights issue means that the Company's share capital increases by a maximum of SEK 8,229,418.92, corresponding to a maximum of 137,156,982 shares and a maximum dilution of 85.7 percent.

The rights issue is secured to 70 percent through subscription commitments and guarantee undertakings from existing and external investors.
To enable the rights issue, the Annual General Meeting resolved to amend the Articles of Association's limits for share capital and number of shares in accordance with the Board's proposal. The new wording is as follows.

§ 4 Share capital
The share capital shall be not less than SEK 6,000,000 and not more than SEK 24,000,000.

§ 5 Number of shares
The number of shares shall be not less than 100,000,000 and not more than 400,000,000.

The AGM also resolved to approve the Board of Directors' proposal to, on one or more occasions during the period until the next Annual General Meeting, resolve to increase the company's share capital within the limits of the Articles of Association. The authorization may only be used to issue shares to those who acted as guarantors in the above-mentioned issue.

All resolutions at the Annual General Meeting were passed unanimously.

Outcome of Warrants Series TO 2

During the period 9-30 March 2023, holders of warrants of series TO 2 have had the right to subscribe for shares with the support of warrants. One (1) warrant of series TO 2 entitles the holder to subscribe for one (1) new share in Prostatype Genomics at a subscription price set at SEK 2.90. A total of 2,622 warrants of series TO 2 have been exercised, corresponding to a subscription of SEK 7,603.80. The utilization entails a dilution of 0.01 percent. Conversion from interim shares to ordinary shares is expected to take place around 19 April 2023 and ordinary shares are expected to be visible on each subscriber's custody account approximately two banking days thereafter.

Collaboration with Spanish Eurofins Megalab

Prostatype Genomics initiates collaboration with Eurofins Megalab, a leader in clinical analysis in the Spanish laboratory market and part of Eurofins, one of the world's largest laboratory groups with operations in Europe, the US, Asia and Latin America. The agreement means that Eurofins Megalab will handle all steps of the laboratory process required to analyze the Prostatype® test on the Spanish and Portuguese markets. The collaboration is another step in Prostatype Genomics' work to further accelerate commercialization in Europe. The agreement will enter into force immediately.

Study with Prostatype® published in leading international journal

The study, conducted by a research team at Uppsala University Hospital led by associate professor and chief physician Michael Häggman, shows that the

Prostatype® gene test correctly assesses the aggressiveness of the prostate cancer tumor when comparing gene expression from tissue samples, so-called biopsies, with the "result", i.e. the operated prostate (radical prostatectomy). The study is now published in The Prostate, a leading peer reviewed publication aimed at, among others, urologists, and pathologists.

Prostatype Genomics recruits Steven Gaal as President of Prostatype Genomics Inc., USA

Prostatype Genomics AB has recruited Steven Gaal to the role of President of the company's wholly owned subsidiary, Prostatype Genomics Inc. Stevens' task will be to establish and launch Prostatype®, the company's gene test for assessing the aggressiveness of prostate cancer in patients, on the US market. Steve has over 18 years of experience from leadership positions in sales of cancer diagnostic tools and services and will join Prostatype Genomics Inc. with immediate effect.

Steven joins Prostatype Genomics Inc. with extensive experience in genomic testing. Steven has experience working in both start-ups and more established companies. He has held senior positions at USLABS (acquired by LabCorp), P4Diagnostix and most recently SkylineDx. As Sales Director at MDxHealth, Steven was instrumental in launching ConfirmMDx for prostate cancer and SelectMDx for prostate cancer to US-based urologists.

Prostatype Genomics AB enters into agreement with Life Genomics AB

Prostatype Genomics and Life Genomics are entering into a non-exclusive collaboration whereby Life Genomics will handle all steps in the laboratory process required to analyze Prostatype, the Prostatype® Genomics gene test to assess the aggressiveness of prostate cancer. The collaboration means that Prostatype Genomics can further focus on marketing the test to patients and doctors and secures resources to be able to handle the increased demand for Prostatype® from patients and healthcare. The agreement applies to all Nordic countries and enters into force immediately.

The collaboration means that Life Genomics will handle the entire process from receiving referrals from healthcare providers to performing and reporting the results of the gene analysis in accordance with Prostatype Genomics' quality-assured processes.

Not 18 Disposal of profit

Amounts in Kr	
The Board of Directors proposes that the funds at its disposal:	
Retained profit	37 156 269
Profit for the year	-29 086 533
Total	**8 069 738**
Carried forward	8 069 738
Summa	**8 069 738**

Managment

Fredrik Persson
CEO since 2017

About: B.Sc in Business Administration and Economics, University of Lund. 30 years of international life science industry experience in leading positions with focus on operational and organizational growth.
Other assignments:
Stradis Med Nordics AB; Chairman of the Board.
Holdings in the Company: 247 953 shares, 72 238 warrants TO 2, 17 615 warrants TO 1 and 25 000 warrants 2020/2023 A.

Mats Bergström
Sales & Marketing Director EMEA since 2022

About: More than 30 years of experience in leading positions in sales and marketing in everything from small start-up companies to leading multinational companies in life science.
Holdings in the Company: 0 shares, 0 options T0 1 and 0 options 2020/2023.

Michael af Winklerfelt
CFO & COO since 2020

About: MBA in Finance & Strategy Concentration, Emory University, USA. M.Sc in Economics and Business Administration, Stockholm School of Economics. Wide-ranging international experience working for multinationals in US, Europe and China.
Other assignments: Director of the Board Ramén Valves AB.
Holdings in the Company:
18 848 shares and 37 206 warrants 2020/2023 A.

Katarina Sjöberg
QA/RA Manager since 2023

About: 30 years of experience from life science of which 14 years as QA Manager.
Holdings in the Company: 0 shares, 0 options T0 1 and options 2020/2023 A.

Emelie Berglund
CTO since 2022

About: PhD in Biotechnology from KTH. 10 years of experience from prostate cancer research including 2 years of working in the private sector to develop diagnostic products.
Holdings in the Company:
11 478 shares, 0 warrants T0 1 and 0 2020/2023 A.

Nicklas Rosendal
Communications Director since 2021

About: BA in Communication & Marketing, Stockholm University. 25 years of experience in marketing, communication, investor relations and patient relations from leading international pharmaceutical companies and leading consulting companies.
Holdings in the Company: 0 shares, 0 options T0 1 and options 2020/2023 A.

Board

Anders Lundberg
Chairman of the Board since 20177

About: M.Sc. Mechanical Engineering, KTH, Stockholm, Sweden. Founder and CEO of a telecom equipment supplier recognized by the market and later brought to a successful IPO in 2011 on the MID-CAP list OMX-Nasdaq [TRMO:Transmode].
Other assignments:
AJ Lundberg Kapitalförvaltning AB;Board member
Modern Car Group International AB ;Board member
Sollentunafastigheter 2 AB; Deputy board member
Sollentunahem AB; Deputy board member.
Holdings in the Company: Via AJ Lundberg Kapitalförvaltning AB 311 509 shares and 0 warrants 2020/2023B Independent in relation to Prostatype Genomics, its senior management and major shareholders.

Håkan Englund
Board member since 2019

About: Courses in polymer technology at Royal Institute of Technology in Stockholm, Sweden. CEO and owner, JDS Invest. More than 30 years of operational and investment experience from life science and health care industry with focus on commercialization and business development. Håkan has held several leading management positions at Pharmacia Biotech and Phadia and has during his career developed extensive national and international relevant networks.
Other assignments: Antrad Medical AB; Board member
BioArctic AB; Board member GlycoBond AB; Deputy board member: SecureAppbox AB;Chairman of the Board Ultimovacs ASA ; Deputy board member (Ending April 2022).
Holdings in the Company: Via JDS Invest AB 707605 shares and 0 warrants 2020/2023BIndependent in relation to Prostatype Genomics, its senior management and major shareholders.

Dr. Michael Häggman
Board member since 2018

About: M.D, Ph.D. associate professor, department of Urology, Akademiska University Hospital, Uppsala, Sweden. More than 30 years of experience practicing as urologist with an extensive national and international network among urologists.
Other assignments: General partner in Skrotum Kommanditbolag and deputy member of the board of Kardinaltalet AB.
Holdings in the Company: 14 817 shares and 0 warrants 2020/2023B. Independent in relation to Prostatype Genomics, its senior management and major shareholders.

Mattias Prage
Board member since 2022

About: Attorney and partner at Advokatfirman Lindahl, specialised in corporate law, financing and contract law.
Holdings in the Company:
0 shares, 0 warrants 2020/2023B. Independent in relation to Prostatype Genomics, its senior management and major shareholders.

Karlheinz Schmelig
Board member since 2013

About: BSc in Business Administration, DHBW Mannheim, Germany. MBA, Kelley School of Business, Bloomington, USA. Managing Director (Geschäftsführer) of Creathor Venture Management GmbH, Bad Homburg (advisor to Creathor Funds).

Other assignments:
Biofrontera AG, Leverkusen, Germany; Supervisory Board Member
Phenex Pharmaceuticals, Heidelberg, Germany; Supervisory Board Member
CryoTherapeutics SA, Awans, Belgium; Supervisory Board Member,
Cevec Pharmaceuticals, Cologne, Germany; Board Member
Tacalyx GmbH, Berlin, Germany; Board Member
Acousia Therapeutics GmbH, Tübingen, Germany. Board Observer.
Holdings in the Company: Representing Creathor Ventures, 3 079 911 shares, 443 561 and 0 warrants 2020/2023 B. Personal holding: 9951 share. Independent in relation to Prostatype Genomics and its senior management. Dependent in relation to major shareholder.

Signatures

Stockholm 2023-05-04

Anders Lundberg
Board member

Håkan Englund
Board member

Dr. Michael Häggman
Board member

Karlheinz Schmelig
Board member

Mattias Prage
Board member

Our audit report was submitted on 2023-05-04
Grant Thornton Sweden AB

Joakim Söderin
Certified accountant


Prostatype
Genomics